文献速递头痛与眩晕

抗CGRP单克隆抗体治疗偏头痛的长期疗效与持续用药因素:EUREkA队列2年结果

Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort.
PubMed 文献 · Neurology · 2026-01-28

该前瞻性观察性多中心注册研究分析了抗CGRP单克隆抗体治疗偏头痛的2年疗效与治疗持续性。1,340例达到24个月的患者中,60.4%实现月头痛天数(MHD)较基线减少≥50%,持续应答比例为53.8%。基线MHD更高、伴先兆、抑郁和肥胖与因疗效不足而停药相关。

要点

  • 抗CGRP单抗治疗2年时60.4%患者MHD减少≥50%,持续应答者占53.8%。
  • 基线MHD更高、伴先兆、抑郁和肥胖者更可能因疗效不足停药。
  • 该研究提供IV级证据支持抗CGRP单抗在24个月内持续减少MHD。

核心结论

  • 抗CGRP单克隆抗体治疗偏头痛在2年时观察到MHD的持续减少。
  • 延迟治疗启动、伴先兆偏头痛、抑郁和肥胖可能对治疗持续性产生负面影响。

研究设计与样本

  • 前瞻性观察性多中心注册研究,分析抗CGRP单克隆抗体治疗偏头痛患者。
  • 1,340例达到24个月随访者纳入ON组(中位年龄48.0岁,81.7%女性),1,057例因疗效不足停药者纳入OFF组。

主要发现

  • 基线中位MHD为20.0天。
  • 24个月时60.4%(809/1,340)患者MHD较基线减少≥50%。
  • 24个月时持续应答(4个时间点中≥3个点MHD减少≥50%)比例为53.8%(142/264)。
  • OFF组较ON组基线MHD更高(ON:20.0天 vs OFF:25.0天),伴先兆(16.2% vs 22.9%)、抑郁(22.8% vs 37.9%)和肥胖(7.2% vs 19.1%)比例更高(p < 0.001)。

关键数值与推荐

  • 持续应答定义为4个时间点(6、12、18、24个月)中≥3个点MHD较基线减少≥50%。
  • 24个月时MHD减少≥50%的患者比例为60.4%(809/1,340)。
  • 24个月时持续应答比例为53.8%(142/264)。

临床怎么用

  • 抗CGRP单抗可用于偏头痛的长期治疗,2年时多数患者可维持MHD减少≥50%。
  • 对基线MHD高、伴先兆、抑郁或肥胖的患者,应关注治疗持续性并加强随访管理。

局限性

  • 本研究为观察性注册研究,证据等级为Class IV。
  • 持续应答分析仅基于264例患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to describe the long-term effectiveness and treatment persistence of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) in migraine and to identify baseline factors associated with 2-year treatment continuation. METHODS: A prospective observational multicenter registry-based study of anti-CGRP MAbs was conducted. We analyzed changes in monthly headache days (MHDs) at 24 months (M24) compared with baseline in those who reached M24 (ON-group). We analyzed patterns of response at 4 time points (6, 12, 18, and 24 months). We defined sustained response (SR) as a ≥50% reduction in MHDs at ≥3 of 4 time points. We compared baseline characteristics of the ON-group with those of the discontinuation group because of lack of effectiveness (OFF-group). RESULTS: A total of 1,340 individuals reached M24 (ON-group: median age 48.0 [41.0-55.0] years; 81.7% female). The median MHD at baseline was 20.0 (13.0-28.0) days. At M24, 60.4% of patients demonstrated ≥50% reduction in MHDs (809/1,340). The proportion of participants achieving SR at M24 was 53.8% (142/264). When compared with the ON-group (n = 1,340), the OFF-group (n = 1,057) showed statistically significant higher baseline MHDs (ON: 20.0 [13.0-28.0] vs OFF: 25.0 [16.0-28.0]) and a greater proportion of patients with aura (ON: 16.2% vs OFF: 22.9%), depression (ON: 22.8% vs OFF: 37.9%), and obesity (ON: 7.2% vs OFF: 19.1%) (p < 0.001). DISCUSSION: Sustained reductions in MHDs to anti-CGRP treatment at 2 years was observed. Delayed treatment onset, migraine with aura, depression, and obesity may negatively affect treatment persistence. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Caronna E, Mas-de-Les-Valls R, Egeo G, et al. Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort. Neurology. 2026. PMID: 41604607. doi:10.1212/WNL.0000000000214659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。